Developing new generation medicines for Central Nervous System (CNS) diseases and disorders with high unmet need

VistaGen Therapeutics (NASDAQ: VTGN) is a clinical-stage biopharmaceutical company focused on developing new CNS medicines with rapid onset therapeutic activity and without the psychological and other side effects and safety concerns that often limit the clinical utility of current treatments for major depressive disorder, neuropathic pain, social anxiety disorder and suicidal ideation.

Our Pipeline

Going Beyond Current Treatment Options for Depression and Social Anxiety Disorder

Learn more about our CNS Pipeline

Experienced Leadership

Our experienced leadership team has a proven track record of developing innovative medicines to treat a wide range of CNS diseases and disorders.

Meet Our Team

Stock Information

View Detailed Stock Info
Nasdaq: VTGN Symbol
Day Range
52 Week Range

Email Updates

Be the first to receive news, events & updates Sign Up